dorsaVi Ltd.

dorsaVi Ltd.

AASX:DVL
0.02
AUD
+0.00
(-4.55%)
0.00EPS
6.77MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.01
- -
- -
- -
Basic EPS, GAAP
- -
-0.03
-0.11
-0.03
-0.02
-0.02
-0.02
-0.03
-0.01
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.15
0.19
0.05
0.05
0.07
0.05
0.03
- -
0.01
- -
- -
- -
- -
Tangible Book Value per Share
0.15
0.19
0.04
0.05
0.05
0.02
0.01
- -
0.01
- -
- -
- -
- -
Basic Weighted Avg Shares
127
110
76
159
175
185
199
231
301
358
467
548
702
Sales/Revenue/Turnover
- -
1
1
3
3
3
3
2
2
2
2
1
- -
Operating Margin (%)
- -
-824.01
-613.21
-203.01
-125.21
-159.89
-209.31
-395.33
-164.93
-120.2
-124.93
-131.31
- -
Depreciation Expense
- -
- -
- -
- -
- -
1
1
1
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-4
-8
-5
-4
-4
-4
-8
-2
-2
-2
-1
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-673.35
-544.1
-173.42
-111.84
-108.56
-159.87
-376.04
-108.52
-65.28
-99.37
-95.66
- -
Working Capital
18
14
6
7
10
8
3
2
3
1
2
1
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
2
1
- -
- -
- -
- -
Total Equity
18
15
6
9
13
9
6
- -
2
1
2
1
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-21.51
-76.86
-70.39
-35.7
-33.47
-52.33
-227.39
-154.7
-90.79
-125.59
-92.34
- -

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2
2024
- -
- -
1
2025
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

CEO
Mathew Regan
Full Time Employees
34
Sector
Electronic technology
Industry
Electronic equipment/Instruments
Address
11-13 Milgate Street Perth VIC Australia 3167
IPO Date
Dec 11, 2013
Business
dorsaVi Ltd develops and sells wearable sensor-based motion analysis technologies for clinical, sports, workplace safety, and research applications. The company offers ViMove+ and ViPerform for clinic and sports solutions including athletic performance assessment, injury risk analysis, physical therapy, and rehabilitation; ViSafe and myViSafe for workplace safety to evaluate manual handling, ergonomic risks, and behavioral changes via self-assessments; and Research+ products with advanced algorithms for biomechanical studies; complemented by telehealth solutions, professional suites, video AI, subscriptions, and replacement parts such as pressure and temperature sensors. Incorporated in 2008 and headquartered in Melbourne, Australia, dorsaVi operates primarily in the United States, Australia, and Europe through two segments—Clinical, which generates the majority of revenue, and Workplace—and commercializes its technologies via direct sales, licenses, or fixed-fee consultancies. In November 2025, dorsaVi acquired a Process-In-Memory neuromorphic IP technology portfolio from Technion Research & Development Foundation Ltd. and Neurofabrica Pty Ltd. for $2.65 million in shares, positioning the company to advance intelligent wearables, robotics, and edge intelligence; it also signed a five-year sales agreement with Select Medical covering over 1,900 U.S. outpatient physical therapy centers.